X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with WYETH LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs WYETH LTD - Comparison Results

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA WYETH LTD NATCO PHARMA/
WYETH LTD
 
P/E (TTM) x 13.3 27.7 47.9% View Chart
P/BV x 3.8 5.3 71.0% View Chart
Dividend Yield % 1.2 1.3 92.1%  

Financials

 NATCO PHARMA   WYETH LTD
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
WYETH LTD
Mar-13
NATCO PHARMA/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs1,0801,044 103.4%   
Low Rs671818 82.1%   
Sales per share (Unadj.) Rs592.1298.6 198.3%  
Earnings per share (Unadj.) Rs188.457.2 329.1%  
Cash flow per share (Unadj.) Rs206.358.4 353.3%  
Dividends per share (Unadj.) Rs8.2517.00 48.5%  
Dividend yield (eoy) %0.91.8 51.6%  
Book value per share (Unadj.) Rs833.6249.5 334.1%  
Shares outstanding (eoy) m36.9022.72 162.4%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x1.53.1 47.4%   
Avg P/E ratio x4.616.3 28.6%  
P/CF ratio (eoy) x4.215.9 26.6%  
Price / Book Value ratio x1.13.7 28.1%  
Dividend payout %4.429.7 14.7%   
Avg Mkt Cap Rs m32,31121,157 152.7%   
No. of employees `0004.80.5 981.9%   
Total wages/salary Rs m3,256400 814.0%   
Avg. sales/employee Rs Th4,522.513,787.4 32.8%   
Avg. wages/employee Rs Th674.0813.0 82.9%   
Avg. net profit/employee Rs Th1,439.02,643.3 54.4%   
INCOME DATA
Net Sales Rs m21,8486,783 322.1%  
Other income Rs m404353 114.6%   
Total revenues Rs m22,2527,136 311.8%   
Gross profit Rs m9,2841,617 574.0%  
Depreciation Rs m66227 2,488.7%   
Interest Rs m1546 2,800.0%   
Profit before tax Rs m8,8721,938 457.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m1,920632 303.7%   
Profit after tax Rs m6,9521,301 534.6%  
Gross profit margin %42.523.8 178.2%  
Effective tax rate %21.632.6 66.3%   
Net profit margin %31.819.2 166.0%  
BALANCE SHEET DATA
Current assets Rs m21,3076,984 305.1%   
Current liabilities Rs m5,9202,056 288.0%   
Net working cap to sales %70.472.6 96.9%  
Current ratio x3.63.4 106.0%  
Inventory Days Days7399 73.8%  
Debtors Days Days10724 444.9%  
Net fixed assets Rs m14,986244 6,134.3%   
Share capital Rs m369227 162.4%   
"Free" reserves Rs m30,3535,441 557.9%   
Net worth Rs m30,7605,668 542.7%   
Long term debt Rs m025 0.0%   
Total assets Rs m37,1517,901 470.2%  
Interest coverage x58.6353.3 16.6%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.9 68.5%   
Return on assets %19.116.5 115.7%  
Return on equity %22.622.9 98.5%  
Return on capital %29.334.0 86.2%  
Exports to sales %00.2 0.0%   
Imports to sales %036.3 0.0%   
Exports (fob) Rs mNA15 0.0%   
Imports (cif) Rs mNA2,465 0.0%   
Fx inflow Rs m10,32215 67,906.3%   
Fx outflow Rs m2,9782,677 111.3%   
Net fx Rs m7,343-2,662 -275.9%   
CASH FLOW
From Operations Rs m4,636923 502.2%  
From Investments Rs m-11,155317 -3,520.0%  
From Financial Activity Rs m6,509-481 -1,353.2%  
Net Cashflow Rs m-18759 -2.4%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 1.5 51.1 2.9%  
Indian inst/Mut Fund % 7.8 11.3 69.4%  
FIIs % 16.6 7.2 231.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 30.4 85.5%  
Shareholders   25,395 21,978 115.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   ORCHID PHARMA LTD  CIPLA  TORRENT PHARMA  ALEMBIC LTD  STERLING BIOTECH  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Recover; Healthcare & IT Stocks Witness Buying(12:30 pm)

Share markets in India have trimmed their early losses and are presently trading marginally lower. Sectoral indices are trading mixed with stocks.

Related Views on News

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Dec 11, 2018 01:33 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - PANACEA BIOTECH COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS